1	
2	Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2
3	convalescent patients who received two doses of mRNA vaccination
4	
5	Yukiya Kurahashi, MD ¹ , Koichi Furukawa, MD ¹ , Silvia Sutandhio, MD ¹ , Lidya Handayani Tjan,
6	MD, PhD ¹ , Sachiyo Iwata, MD, PhD ² , Shigeru Sano, MD, PhD ³ , Yoshiki Tohma, MD ³ ,
7	Hiroyuki Ohkita, MD ⁴ , Sachiko Nakamura, MD ⁴ , Mitsuhiro Nishimura, PhD ¹ , Jun Arii, DVM,
8	PhD ¹ , Tatsunori Kiriu, MD, PhD ⁵ , Masatsugu Yamamoto, MD, PhD ⁶ , Tatsuya Nagano, MD,
9	PhD ⁶ , Yoshihiro Nishimura, MD, PhD ⁷ , Yasuko Mori, MD, PhD ^{1*}
10	
11	¹ Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School
12	of Medicine, Kobe, Hyogo, Japan
13	² Division of Cardiovascular Medicine, Hyogo Prefectural Kakogawa Medical Center,
14	Kakogawa, Hyogo, Japan
15	³ Acute Care Medical Center, Hyogo Prefectural Kakogawa Medical Center, Kakogawa, Hyogo,
16	Japan
17	⁴ Division of General Internal Medicine, Hyogo Prefectural Kakogawa Medical Center,
18	Kakogawa, Hyogo, Japan
19	⁵ Division of Respiratory Medicine, Hyogo Prefectural Awaji Medical Center, Sumoto, Hyogo,
20	Japan
21	⁶ Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate
22	School of Medicine, Kobe, Hyogo, Japan

23	⁷ Kita-Harima Medical Center, Ono, Hyogo, Japan
24	
25	* Correspondence:
26	Corresponding Author: Yasuko Mori, MD, PhD ¹ *
27	ymori@med.kobe-u.ac.jp
28	
29	Keywords: SARS-CoV-2, COVID-19, Omicron, cross-neutralizing antibody, convalescent
30	
31	Running title: Cross-neutralizing antibody against Omicron
32	
33	Words: abstract 85/100, main: 1,974/2000
34	

36 Abstract

- 37 The SARS-CoV-2 variant Omicron is now under investigation. We evaluated cross-neutralizing
- 38 activity against Omicron in COVID-19 convalescent patients (n=23) who had received two doses
- 39 of an mRNA vaccination (BNT162b2 or mRNA-1273). Surprisingly and interestingly, after the
- 40 second vaccination, the subjects' neutralizing antibody titers including that against Omicron all
- 41 became seropositive, and significant fold-increases (21.1–52.0) were seen regardless of the
- 42 subjects' disease severity. Our findings thus demonstrate that at least two doses of mRNA
- 43 vaccination to SARS-CoV-2 convalescent patients can induce cross-neutralizing activity against
- 44 Omicron.
- 45

46 BACKGROUND

47	The Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
48	syndrome coronavirus 2 (SARS-CoV-2) has been a major public health problem worldwide since
49	November 2019. As of mid-January 2022, more than 310 million individuals worldwide have
50	been infected with SARS-CoV-2, and more than 5.5 million have died [1]. The threat posed by
51	the SARS-CoV-2 variant Omicron (B.1.1.529) is now under intensive investigation. Omicron
52	was first detected in Botswana on 11 November 2021 and in South Africa on 14 November
53	2021, and the rate of increase in the number of individuals infected with this variant has been
54	explosive.
55	In the efforts to control the spread of Omicron, a major challenge has been the low
56	seroconversion rates of cross-neutralizing antibody against Omicron in sera of the individuals
57	who are fully COVID-19-vaccinated [2]. A booster dose of an mRNA vaccine for individuals'
58	acquisition of sufficient cross-neutralizing ability has been recommended by several
59	investigators [3–5] and our research group [6], but as of this writing the data regarding the cross-
60	neutralizing activity against Omicron in COVID-19 convalescent individuals following mRNA
61	vaccination are lacking $[5, \Box 7, \Box 8]$.
62	As elsewhere worldwide, the population of Japan has been attempting to overcome the
63	COVID-19 pandemic. As of mid-January 2022, nearly 1,800,000 Japanese people have been
64	infected with COVID-19, and approx. 18,000 people had died due to this disease [1]. The sixth
65	wave (i.e., surge in new COVID cases) in Japan has been due to the Omicron variant. To control
66	this pandemic in Japan, BNT162b2 vaccination (more commonly known as the Pfizer COVID-
67	19 vaccine) was started in mid-February 2021, and mRNA-1273 vaccination (the Moderna

68 COVID-19 vaccine) was started in mid-May 2021. As of mid-January 2022, 78.9% of Japan's
69 population was fully vaccinated [9].

It is important to determine whether the COVID-19 convalescent patients have crossneutralizing activity against Omicron, because cross-neutralizing activity is the key to protection against reinfection. We thus conducted the present study to evaluate the neutralizing activity against the Delta and Omicron variants in the sera of COVID-19 convalescent patients. We also evaluated the efficacy of two doses of mRNA vaccine by analyzing the neutralizing antibody titer against Omicron in the same individuals.

77 **METHODS**

78 Diagnosis of COVID-19 and definition of severities

79 A positive SARS-CoV-2 antigen test or positive polymerase chain reaction (PCR) 80 detection of the SARS-CoV-2 genome in nasal, nasopharyngeal, or opharyngeal, or saliva 81 samples were used to confirm the diagnosis of COVID-19. We used the same definitions of 82 severities as in our previous reports $[10, \Box 11]$; 'Asymptomatic' patients had neither clinical 83 symptoms nor hypoxia. 'Mild' patients had symptoms without evidence of pneumonia or 84 hypoxia. 'Moderate' patients had clinical symptoms of pneumonia with oxygen saturation levels 85 >90% on room air. 'Severe' patients suffered from pneumonia with an oxygen saturation level 86 <90% on room air. 'Critical' patients needed mechanical ventilation. In the present study, we also 87 refer to one group as 'patients without pneumonia'; this group included the patients who did not 88 present with pneumonia (asymptomatic and mild patients). Another group is referred to as 89 'patients with pneumonia', comprised of the patients who presented with pneumonia (moderate, 90 severe and critical patients).

91

92 Study site and patient recruitment

93	Serial sera samples of COVID-19 patients have been collected by Hyogo Prefectural					
94	Kakogawa Medical Center (Kakogawa, Hyogo, Japan) at various timepoints post-onset: 1-3, 3-					
95	6, and 6–9 months post-onset, and approx. 12 months post-onset. In this study, the sera of					
96	patients infected between 10 March 2020 and 5 January 2021 are called 'Term 1', those of					
97	patients infected between 28 April 2021 and 26 May 2021 are called 'Term 2', and those of					
98	patients infected between 10 March 2020 and 5 January 2021 are called 'Term 3' excluding the					
99	patients given therapeutic monoclonal antibody drugs.					
100	We examined the neutralizing antibody titers among SARS-CoV-2 convalescent patients.					
101	Based on the epidemiological data [12], it is likely that the patients in Term 1 were infected with					
102	D614G, those in Term 2 were infected with Alpha, and those in Term 3 were infected with Delta.					
103	We therefore compared the neutralizing antibody titers against D614G, Delta, Omicron in Term					
104	1; we compared the titers against Alpha, Delta, Omicron in Term 2, and we compared those					
105	between Delta and Omicron in Term 3.					
106						
107	Virus strains					
108	The SARS-CoV-2 Biken-2 (B2) strain and the D614G reference variant (accession no.					
109	LC644163) received from BIKEN Innovative Vaccine Research Alliance Laboratories were					
110	used. The SARS-CoV-2 variants B.1.1.7 Alpha variant (GISAID ID: EPI_ISL_804007),					
111	B.1.167.2 Delta variant (GISAID ID: EPI_ISL_2158617), and B.1.1.529 Omicron variant					
112	(GISAID ID: EPI_ISL_7418017) were obtained from the National Institute of Infectious					

113 Diseases (NIID), Tokyo.

114

115 Neutralization assay

116	The virus neutralization assay against the four SARS-CoV-2 variants D614G, Alpha, Delta,
117	and Omicron was conducted using each authentic virus as described [10, 11] at Biosafety Level
118	3.
119	
120	Statistical analyses
121	Continuous variables are described using medians and interquartile ranges (IQRs) defined
122	by the 25th and 75th percentiles. Categorical factors are reported as counts and percentages. The
123	neutralizing antibody titers under two were assigned a titer of one for the geometric mean titer
124	(GMT) calculations. The Wilcoxon signed-rank test or Friedman's test and Bonferroni correction
125	were performed to compare the neutralizing antibody titers. The level of statistical significance
126	in all analyses was set at $P < .05$. Statistical analyses were performed using STATA (ver. 14.2).
127	Sample size calculation was not performed.
128	
129	Ethics
130	Our study was approved by the Ethics Committees of Kobe University Graduate School of
131	Medicine (ID: B200200) and Hyogo Prefectural Kakogawa Medical Center. Written consent or
132	the opt-out consent for our observational study was obtained.
133	
134	RESULTS
135	The patients' characteristics

136	We assessed 40 sera of Term 1 patients, 12 sera of Term 2 patients, and 16 sera of Term 3				
137	patients (Supplementary Table 1 and 2). We used four groups for the sera based on the four				
138	time periods of blood sampling (1–3, 3–6, 6–9, and 12months post-onset). The numbers of				
139	patients with pneumonia were Term 1 (n=22), Term 2 (n=12), and Term 3 (n=16). The number				
140	of convalescent patients who had received two doses of a vaccine (BNT162b2 or mRNA-1273)				
141	was 19 in Term 1 and four in Term 2.				
142					
143	Comparison of the neutralizing antibody titers against variants in the patients' sera				
144	We compared the neutralizing antibody titers against SARS-CoV-2 variants from the sera				
145	of the COVID-19 convalescent patients. These sera were collected at 1–3 months post-onset				
146	(Figure 1A, 1B, Supplementary Figure 1, and Supplementary Table 3). The seropositive				
147	rates of neutralizing antibody were 97.5% for D614G, 87.5% for Delta, and 37.5% for Omicron				
148	(Figure 1A). The GMTs of neutralizing antibody were 18.7 against D614G, 7.7 against Delta,				
149	and 1.5 against Omicron (Supplementary Table 3).				
150	The results of our comparison of the neutralizing antibody titers against D614G, Delta, and				
151	Omicron in the patients with or without pneumonia in Term 1 are provided in Supplementary				
152	Figure 1 and Supplementary Table 3. Although the GMTs of neutralizing antibody in the				
153	patients with pneumonia in Term 1 were higher than those of the patients without pneumonia, the				
154	seropositive rate of the Term 1 patients with pneumonia was only 59.1% and the GMT of				
155	neutralizing antibody against Omicron was 2.0, the same as the cut-off point.				
156	We next compared the neutralizing antibody titers against D614G, Alpha, or Delta with				
157	those of Omicron in the patients with pneumonia in Term 1 to Term 3 (Figure 1B). We aligned				
158	the severity among the patient groups because there were no sera of Term 2 or Term 3 patients				

159	without pneumonia. Significant fold-decreases of neutralizing antibody titers against Omicron				
160	relative to those against the other variants were observed: 17.6 ($P < .0001$) for Term 1, 12.0 ($P < .0001$)				
161	.0001) for Term 2, and 13.5 (<i>P</i> < .0001) for Term 3.				
162					
163	Longitudinal analysis of neutralizing antibody titers against D614G, Alpha, Delta, and				
164	Omicron in patients infected in Term 1 or Term 2 after two vaccine doses				
165	We examined the trends of neutralizing antibody titers in the patients infected during				
166	Term 1 after their two doses of vaccination at 1–3, 3–6, 6–9, and 12months post-onset (n=19)				
167	(Figure 2A and Supplementary Table 4). Two doses of mRNA vaccination were completed				
168	before the sera were collected at 12months post-onset. The GMTs of the neutralizing antibody				
169	against D614G and Delta tended to decline from 1–3 months post-onset to 6–9 months post-				
170	onset. The GMTs of the neutralizing antibody against Omicron were under two among three				
171	sampling points. Surprisingly and interestingly, after the two doses of vaccination, all				
172	neutralizing antibody titers including that against Omicron became seropositive and showed				
173	significant fold-increases (21.1 to 52.0) regardless of the severity of the patients' disease				
174	(Figures 2A and 2C, Supplementary Figure 2A, and 2B).				
175	We then evaluated the trend of neutralizing antibody titers in the patients infected during				
176	Term 2 and subsequently vaccinated at 1–3, 3–6, and 6–9 months post-onset (n=4) (Figures 2B,				
177	2D, and Supplementary Table 3). Two doses of the vaccination were completed before the sera				
178	were collected at 6–9 months post-onset. The GMTs of the neutralizing antibody against Alpha,				
179	Delta, and Omicron tended to decline from 1–3 months post-onset to 3–6 months post-onset.				
180	After two doses of the vaccination, a significant fold-increase of the neutralizing antibody titers				
181	against Omicron was also observed (Figures 2B and 2D), indicating that the neutralizing				

182	antibody against Omicron has been boosted by the vaccination; however, the neutralizing
183	antibody titers against Omicron were significantly lower than those against the variants which
184	were suspected to have infected patients (D614G or Alpha) even after vaccination (Figure 2C,
185	2D, Supplementary Figure 2C, and 2D).
186	
187	DISCUSSION
188	The results of our analyses revealed that the neutralizing antibody titers against Omicron
189	in the patients infected in Term 1 were remarkably decreased (Figure 1A, Supplementary
190	Figure 1 and Supplementary Table 3). Notably, the seropositive rate of neutralizing antibody
191	titer against Omicron in the patients without pneumonia in Term 1 was only 11.1%. These data
192	are similar to those of earlier studies $[7, \Box 8, \Box 13]$. The seropositive rate against Omicron of the
193	patients with pneumonia was higher than that of the patients without pneumonia because a
194	stronger immune response was elicited in the severe COVID-19 patients compared to those with
195	mild disease (Supplementary Figure 1) [10].
196	Our findings also demonstrated significant fold-decreases against Omicron relative to
197	D614G (×17.6), Alpha (×12.0), and Delta (×13.5) (Figure 1B). Another study showed clear fold-
198	decreases against Omicron compared to Victoria (an early pandemic strain; ×16.9), Alpha
199	(\times 18.4), and Delta (\times 25.9) [7]. In the present study, the proportion of patients whose condition
200	was considered 'critical' in Term 3 (75%) was much higher than those in Term 1 (9%) and Term
201	2 (58%), this might have contributed to the lesser fold-decrease against Omicron relative to Delta
202	than expected. Our results suggest that patients who have been infected with any SARS-CoV-2
203	variant could be possibly reinfected with Omicron.

204	We also observed that the neutralizing antibody titers against Omicron increased after two
205	doses of mRNA vaccine in Term 1 and Term 2, as in other studies (Figure 2A, 2B,
206	Supplementary Figure 2A, 2B and Supplementary Table 4) [5, 13]. It was reported that the
207	neutralizing antibody activity against Omicron in convalescent patients who were subsequently
208	vaccinated was around ten times higher than that in fully vaccinated patients without past
209	infection $[5, \Box 13]$. In the present investigation, the ratios of the neutralizing antibody titer against
210	Omicron relative to the other variants (D614G or Alpha) from vaccinated patients after their
211	recovery (Figure 2C and 2D) were almost the same as those against Omicron compared to the
212	D614G in uninfected individuals who received three doses of COVID-19 mRNA vaccine
213	[4, \Box 8, \Box 13]. Although it remains unknown whether one dose is sufficient for convalescent
214	patients with severe symptoms and whether a third dose is necessary for convalescent patients
215	with mild symptoms, our results show that at least two doses of mRNA vaccination to SARS-
216	CoV-2 convalescent patients may induce cross-neutralizing activity against Omicron comparably
217	to three doses of mRNA vaccination to uninfected individuals.
218	
219	
220	Footnotes
221	Conflict of interest
222	The authors declare no conflicts of interest associated with this manuscript.
223	
224	Funding/Support
225	This work was supported by Hyogo Prefectural Government and the Kansai Economic
226	Federation (KANKEIREN). The funders had no role in this study.

227 Meeting

228 This study has never been presented anywhere.

229

230 **Corresponding author:**

- 231 Yasuko Mori, MD, PhD
- 232 Division of Clinical Virology, Center for Infectious Diseases Kobe University Graduate School
- 233 of Medicine 7-5-1 Kusunoki-cho, Chuo-ku, Hyogo 650-0017, Japan.
- 234 Tel: +81-78-382-6272, Fax: +81-78-382-6879
- 235 E-mail: <u>ymori@med.kobe-u.ac.jp</u>

236

237 Acknowledgments

- 238 We thank Kazuro Sugimura MD, PhD (Superintendent, Hyogo Prefectural Hospital Agency and
- 239 Professor, Kobe University) for his full support to promote this study. We express our sincere
- 240 gratitude for cooperation and participation of staffs of Hyogo Prefectural Kakogawa Medical
- 241 Center. We thank for BIKEN Innovative Vaccine Research Alliance Laboratories providing
- 242 SARS-CoV-2 B2 strain. We thank the National Institute of Infectious Disease Japan for
- 243 providing SARS-CoV-2 Alpha, Delta, and Omicron variants. YK obtained Taniguchi Memorial
- 244 Scholarship program founded by BIKEN Foundation. SS¹ and LT got Japanese Government
- 245 (Monbukagakusho:MEXT) Scholarships.

246

247 Author Contributions

- All authors contributed to the concept of this article. YK drafted the manuscript; YM provided
- revisions; YK, JA, MN, and YM analyzed the data; YK, KF, SS¹, and LT did the experiments;

YM and YN supervised the experiments; SI, YT, SS³, SN, TK, MY and TN collected the
samples; YM conducted the project; All authors approved the final version of the manuscript

252

253 Figure legends

254

255 Figure 1. Comparison of the neutralizing antibody titers against D614G, Alpha, Delta, and 256 **Omicron from sera of convalescent COVID-19 patients.** Vertical bar: The neutralizing 257 antibody titer (log2 scale). Horizontal bar: The SARS-CoV-2 variants. All samples in panels A 258 and **B** were collected at 1-3 months post-onset. A: The neutralizing antibody titers of the Term 1 259 patients. B: The neutralizing antibody titers in the patients with pneumonia infected during 260 Terms 1–3. Wilcoxon signed-rank test or Friedman's test and Bonferroni correction were 261 performed to compare the neutralizing antibody titers. Fold-decreases of neutralizing antibody 262 titer (Delta relative to D614G or Alpha, and Omicron relative to D614G, Alpha, or Delta) are 263 above each graph; seropositive rates are below each graph. Gray dash in each graph: The cut-off 264 titer. D614G, Alpha, and Delta are suspected to have infected the individuals in Terms 1, 2, and 265 3, respectively.

266

Figure 2. Comparison of the neutralizing antibody titers against D614G/Alpha, Delta, and Omicron in the patients infected during Term 1 or 2 and subsequently vaccinated. The neutralizing antibody titers against Delta, and Omicron in the patients infected during Term 1 and subsequently vaccinated (A) and the patients infected during Term 2 and subsequently vaccinated (B). C: Comparison of the neutralizing antibody titers against D614G, Delta, and Omicron from the same sera as in panel A collected at 12 months post-onset. D: Comparison of

273	the neutralizing antibody titers against Alpha, Delta, and Omicron in the same sera as in panel B
274	collected at 6–9 months post-onset. Vertical bar: The neutralizing antibody titer (log2 scale).
275	Horizontal bar: The timing of sampling (months post-onset) (A, B) or the SARS-CoV-2 variants
276	used in the virus neutralizing assay (C, D). Boxes: The SARS-CoV-2 variants. Friedman's test
277	and Bonferroni correction were performed to compare the neutralizing antibody titers. Fold-
278	increases of neutralizing antibody titer (12 months post-onset relative to 6–9 months post-onset
279	in A , and 6–9 months post-onset relative to 3–6 months post-onset in B) are shown above each
280	graph. Fold-decreases of neutralizing antibody titer against Delta and Omicron relative to D614G
281	are indicated in C , and those against Delta and Omicron relative to Alpha are indicated in D .
282	Seropositive rates are shown below each graph. Gray dash in each graph indicates the cut-off
283	titer. One serum at 6–9 months post-onset was missing in the group of patients infected during
284	Term 1 and subsequently vaccinated. An arrow in each graph shows the timepoint of the second
285	mRNA vaccination. D614G and Alpha are suspected to have infected the patients during Terms
286	1 and 2, respectively.

287

288 **References**

289 1. worldmeter. COVID-19 CORONAVIRUS PANDEMIC. Available at:
 290 <u>https://www.worldometers.info/coronavirus/</u>. Accessed 9 February 2022.

291 2. Dejnirattisai W, Shaw RH, Supasa P, et al. Reduced neutralisation of SARS-CoV-2 omicron

- B.1.1.529 variant by post-immunisation serum. Lancet **2022**; 399:234-6.
- 293 3. Muik A, Lui BG, Wallisch AK, et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2
- mRNA vaccine-elicited human sera. Science 2022:eabn7591.

- 4. Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 Vaccination Neutralization of SARS-
- 296 CoV-2 Omicron Infection. New England Journal of Medicine **2022**; 386:492-4.
- 5. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine
- 298 boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 2022;

299 185:457-66.e4.

- 300 6. Furukawa K, Tjan LH, Kurahashi Y, et al. Acquired neutralizing breadth against SARS-CoV-
- 301 2 variants including Omicron after three doses of mRNA COVID-19 vaccination and the vaccine
- 302 efficacy. medRxiv **2022**:2022.01.25.22269735.
- 303 7. Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread
 304 escape from neutralizing antibody responses. Cell 2022; 185:467-84.e15.
- 8. Lusvarghi S, Pollett SD, Neerukonda SN, et al. SARS-CoV-2 Omicron neutralization by
 therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster. bioRxiv
 2021:2021.12.22.473880.
- 308 9. World Health Organaization Data. Coronavirus (COVID-19) Vaccinations. Available at:
 309 https://ourworldindata.org/covid-vaccinations. Accessed 9 February 2022.
- 310 10. Tjan LH, Furukawa K, Nagano T, et al. Early Differences in Cytokine Production by
- 311 Severity of Coronavirus Disease 2019. J Infect Dis **2021**; 223:1145-9.
- 312 11. Furukawa K, Tjan LH, Sutandhio S, et al. Cross-Neutralizing Activity Against SARS-CoV-2
- 313 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan. Open Forum
 314 Infect Dis 2021; 8:ofab430.
- 315 12. Outbreak.info. Japan Variant Report. Available at: ttps://outbreak.info/location316 reports?loc=JPN. Accessed 9 Feburary 2022.

- 317 13. Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-
- 318 CoV-2 Omicron antigenic shift. Nature **2021**.

Figure 1



Figure 2



Supplementary Figure 1



Supplementary Figure 1. Comparison of the neutralizing antibody titers against D614G, Delta, and Omicron in the patients infected during Term 1, by severity. *Vertical bar:* The neutralizing antibody titer (log2 scale). *Horizontal bar:* The SARS-CoV-2 variants. All samples were collected at 1–3 months post-onset. The neutralizing antibody titer in the patients infected during Term 1, those without pneumonia in Term 1, and those with pneumonia in Term 1 are shown. Friedman's test and Bonferroni correction were used to compare the neutralizing antibody titers. Fold-decreases of neutralizing antibody titer (Delta relative to D614G, and Omicron relative to D614G) are shown above each graph. Seropositive rates are shown below each graph. *Gray dash* in each graph indicates the cut-off titer. D614G is thought to have infected the patients during Term 1.



Supplementary Figure 2. Comparison of the neutralizing antibody titers against D614G, Delta, and Omicron in the patients infected during Term 1 and subsequently vaccinated, by severity. Comparison of the neutralizing antibody titers against D614G, Delta, and Omicron in the patients without pneumonia in Term 1 and subsequently vaccinated (A) and in the patients with pneumonia in Term 1 and subsequently vaccinated (B). Comparison of the neutralizing antibody titers against D614G, Delta, and Omicron in the same sera as in panel A collected at 12 months post-onset (C). Comparison of the neutralizing antibody titers against Alpha, Delta, and Omicron in the same sera as in panel **B** collected at 12 months post-onset (D). Vertical bar: The neutralizing antibody titers (log2 scale). Horizontal bar: The timing of sampling (months post-onset) (A, B) or SARS-CoV-2 variants used in the virus neutralizing assay (C, D). Boxes: The SARS-CoV-2 variants. Friedman's test and Bonferroni correction were performed to compare the neutralizing antibody titers. Fold-increases of the neutralizing antibody titers (12 months post-onset relative to 6-9 months post-onset in A, and 6-9 months post-onset relative to 3–6 months post-onset in **B**) are shown above each graph. Fold-decreases of the neutralizing antibody titers against Delta and Omicron relative to D614G are indicated in C and D. Seropositive rates are shown below each graph. Gray dash in each graph indicates the cut-off titer. One serum at 6-9 months post-onset was missing in the group of patients infected during Term 1 and subsequently vaccinated. An arrow in each graph indicates the timepoint of the second mRNA vaccination. D614G is thought to have infected the patients during Term 1.

Supplementary Table 1

Characteristics of convalescent patients					
Convalescent patients		Term 1	Term 2	Term 3	
infected with SARS-CoV-2		(n=40)	(n=12)	(n=16)	
	Age ^a (median with IQR)		56	67	58
			(48.5-61.5)	(55.5-72.5)	(52.5-59)
	Sex-Female (n w	vith %)	21 (52.5%)	3 (25%)	4 (25%)
Same	ling times of some	1-3 months	40	12	16
Samp	ling time of sera	3-6 months	40	4	-
Post	month onset (n)	6-9 months	35	4	-
		12 months	19	-	-
	D roumonia()	Asymptomatic	3	0	0
Correction	Pneumonia(-)	Mild	15	0	0
Severity	Pneumonia(+)	Moderate	5	0	0
(11)		Severe	15	5	4
		Critical	2	7	12
Completed two dose of mRNA vaccine		19	4	0	

a: Age are counted when patients were enrolled in our study.

Supplementary Table 2

Median days post onset of sampling sera for SARS-CoV-2 convalescent patients						
Sera Sampling time (month post onset) Median d		an days with IQR				
	1-3m (n=40)	46.5	(42.5-54)			
Тонно 1	3-6m (n=40)	116.5	(109-132)			
Term 1	6-9m (n=35)	202	(197-215)			
	12m (n=19)	379	(368-395)			
	1-3m (n=12)	41	(34.5-48)			
Term 2	3-6m (n=4)	108.5	(100.5-119)			
	6-9m (n=4)	199.5	(192.5-209)			
Term 3	1-3m (n=21)	43	(39-51)			

Supplementary Table 3

in sera of SARS-Cov-2 convarescent patients at 1-5 months onset			
Sera	Variant	GMT of neu	ıtralizing antibody ^a
	D614G	18.7	(13.1-26.6)
1 term 1	Delta	7.7	(5.4-11.0)
(n=40)	Omicron	1.5	(1.2 - 1.9)
1	D614G	8.6	(5.3-14.0)
Ierm I	Delta	3.4	(2.2 - 5.4)
without pneumonia (n=18)	Omicron	1.1	(1.0 -1.2)
	D614G	35.2	(25.2-49.0)
with pneumonia (n=22)	Delta	15.0	(10.7-21.1)
	Omicron	2.0	(1.5 - 2.7)
	Alpha	60.4	(40.6-89.8)
1 term 2	Delta	18.0	(13.1-24.6)
with pheumonia (n=12)	Omicron	5.0	(2.3-11.3)
Term 3	Delta	133.7	(94.9-188.4)
with pneumonia (n=16)	Omicron	9.9	(5.3 - 18.6)

Geometric mean titers (GMTs) of neutralizing antibody

a: Neutralizing antibody titers under two were assigned a titer of one for geometric mean titer (GMT) calculations. GMTs were shown with 95% CI.

in sera of SARS-CoV-2 convalescent patients at 1-3 months onset

Supplementary Table 4

in sera of S.	ARS-CoV-2	convalescent, subs	equently vac	ccinated patients
Sera	Virus	Month post onset	GMT of ne	eutralizing antibody ^a
		1-3m	21.4	(13.0-35.4)
	D614G	3-6m	16.6	(9.8-28.1)
Patients infected during Term 1,		6-9m	11.8	(7.3-18.9)
		12m	368.7	(215.2-631.6)
	Delta	1-3m	10.3	(5.9-18.1)
		3-6m	6.0	(3.9-9.1)
subsequently		6-9m	4.7	(2.7-8.1)
vaccinated (n=19)		12m	171.4	(103.7-283.1)
		1-3m	1.5	(1.1-2.1)
	Omianan	3-6m	1.7	(1.2-2.4)
	Omicron	6-9m	1.5	(1.1-2.0)
		12m	51.4	(25.6-103.1)
		1-3m	11.3	(4.7-27.2)
	D614G -	3-6m	8.0	(4.0-16.0)
		6-9m	5.7	(3.3-9.7)
		12m	279.2	(79.5-980.1)
Patients infected		1-3m	4.8	(2.0-11.3)
during Term 1,	Delta -	3-6m	3.4	(1.6-7.1)
subsequently vaccinated without		6-9m	2.4	(1.2-4.7)
		12m	117.4	(41.2-334.6)
pheumonia (n–8)		1-3m	1.1	(0.9- 1.3)
		3-6m	1.2	(0.9- 1.6)
	Omicron	6-9m	1.1	(0.9- 1.3)
		12m	12m 26.9 (7.0-102.9)	(7.0-102.9)
		1-3m	34.1	(20.1-57.8)
	D(140	3-6m	28.2	(14.7-54.2)
Patients infected	D614G	6-9m	21.1	(12.4-36.0)
during Term 1,	during Term 1,	12m	451.4	(273.1-745.9)
subsequently		1-3m	18.1	(9.8-33.7)
vaccinated with		3-6m	9.1	(6.0-13.6)
pneumonia (n=11)	Delta -	6-9m	8.0	(3.8-16.8)
		12m	225.7	(131.0-388.7)
	Omicron	1-3m	2.0	(1.2-3.3)

Geometric mean titers (GMTs) of neutralizing antibody

		3-6m	2.2	(1.4-3.7)
		6-9m	1.9	(1.1-3.2)
		12m	82.3	(37.5-180.9)
Patients infected during Term 2, subsequently vaccinated (n=4)		1-3m	38.1	(21.9-66.1)
	Alpha	3-6m	22.6	(12.0-42.8)
		6-9m	362.0	(120.1-1090.8)
		1-3m	13.5	(7.8-23.4)
	Delta	3-6m	9.5	(5.5-16.5)
		6-9m	152.2	(52.9-437.6)
		1-3m	4.0	(0.7-24.2)
	Omicron	3-6m	2.8	(1.5-5.3)
		6-9m	90.5	(21.8-375.9)

a: Neutralizing antibody titers under two are assigned a titer of one for geometric mean titer (GMT) calculations. GMTs were shown with 95% CI.